RPost

We’re not just securing email and e-signing.

We’re helping clinical researchers speed drug development to help the wellbeing of more people faster.

And we’ve been doing it with them since 2013.

E-Sign & E-Mail Security for Clinical Research, Biotech, Pharma

RMail & RSign

E-Signatures: Main Uses

E-signatures for clinical research physician and patient onboarding forms

Email Security: Main Uses

Prove delivery and compliance for SUSAR (clinical trial safety notices for adverse reactions) and protecting privacy of patient and clinical trial data.

Popular Features

RMail Gateway email encryption automation, Registered Email e-delivery proof with API for automation, RSign e-signatures with templates.

Industry Accolades

Top five largest global CROs moved critical SUSAR notices to certified and secure email notifications with RMail® Registered Email™ service.

opening quote

ICON has automated SUSAR notifications worldwide using high speed RMail Rest APIs connected to its Pega contact management platform.

closing quote

Features & Benefits

RMail Registered Email™ Delivery Proof for Suspected Unexpected Serious Adverse Reaction Notices Transforms Clinical Trial Operations

In clinical trials, sponsors’ standard operating procedures should contain a minimum requirement for expedited reporting of Suspected Unexpected Serious Adverse Reaction (SUSAR) notices to clinical research physicians / investigators. Timely notice reduces risk of additional adverse reactions including death, by speeding awareness of any reaction issues. Proof of timely e-delivery of these notices to investigators protects the sponsor (pharmaceutical, biotech, life science, medical device companies) and their contract research organizations (CRO), and all involved.

Regulations in the USA, Europe, Canada and other countries require reporting to the appropriate regulator within 15 days of awareness of the SUSAR. Proof of timely e-delivery of these reports to regulators is essential for an auditable proof record of compliance.

RMail Security Automation services provide simple ways to integrate sending encrypted Registered Email messages from existing business process systems like Pega, Oracle, SAP, Salesforce.com, and specialty CRO and CRM systems. This include automated sending with security gateway and email routing policies, SMTP address re-routing, and high-speed REST APIs for sending and retrieving e-delivery evidence data.

Email encryption for HIPAA and GDPR privacy compliance automatically delivers email in a unique way to each recipient, creating the simplest user experience for the recipient while returning auditable proof of privacy and compliance to the sender– going far beyond basic TLS and link-retrieval systems. RMail includes different levels of encryption for when it is important to keep messages private from the recipient’s email administrator or email systems like Gmail, and others who may otherwise have access to their email.

RMail transmission encryption is most popular among health care professionals when communicating referrals, lab results or other private patient information. RMail message-level encryption is most popular when communicating patient information that is very sensitive.

RSign® e-signatures are the simplest to use, most affordable full featured web-based electronic signature service. RSign makes it easy for signers to complete and sign documents using any desktop or mobile web browser in an intuitive, guided signing process.

RSign is the easiest way to obtain patient information filled into forms sent by email or posted on websites, with the completed form compiled as a PDF record and with options to automatically back-fill form data into the health care information management system.

Peer Reviews

opening quote

Some of the world’s largest contract research organizations including ICON plc have defined their SUSAR notification policies to include sending by RMail® Registered Email™ service, with automatic encryption direct delivery, to ensure timely delivery with auditable proof of notice to protect from adverse reaction risk and for proof of regulatory notice compliance.

closing quote

Amgen enhanced its electronic clinical research system with RMail secure electronic messaging.

Amgen, an American multinational biopharmaceutical company headquartered in California, integrated RMail so that certain physician packages could be transmitted via Registered Email™ services with encryption when needed; importantly returning proof of delivery of disclosures to reduce risk. With RMail’s easy-to-use, cost-effective and award-winning Registered Email™ service, Amgen was able to transmit essential documentation with returned delivery evidence, thereby complying with requirements.

Amgen is one of the world’s largest life sciences companies with specialty in biotechnology. We’ve been providing assurance that critical medical disclosure packages are reaching researchers and physicians, to reduce risk of a missed critical communication; and to provide auditable, timestamped proof of content successful delivery.

Requirements: Legal & Compliance

Registered Email™ services provide proof of delivery compliance for Suspected Unexpected Serious Adverse Reaction (SUSAR) notices to clinical research physicians / investigators. Regulations in the USA, Europe, Canada and other countries require reporting to the appropriate regulator within 15 days of awareness of the SUSAR.
RMail® email encryption provides simple to use and automated privacy compliance for HIPAA, GDPR, and other state and country regulations protecting personal private information, returning auditable proof of privacy compliance in the form of a Registered Receipt™ email record for each message sent.

Discalimer: Neither nor its affiliates provide legal opinions. The information on RPost and its affiliates and products websites is for general information purposes only and is not intended to serve as legal advice or to provide any legal opinions. Laws and regulations change from time to time and neither RPost nor its affiliates guarantee that all of the information on RPost and its affiliates websites are current, correct, or with sufficient detail for the purpose of each reader. You should consult your legal counsel for specific jurisiction and issues.
Tradenames are owned by the named company. Service benefit is summary, not intended to be a case study.​ RPost technology is patented. RMail, RSign, and RPost are trademarks owned by RPost.